. Author manuscript; available in PMC: 2014 Sep 1.

Published in final edited form as: J Vasc Surg. 2013 Apr 13;58(3):635–42.e2. doi: 10.1016/j.jvs.2013.02.036

Table III.

Categorization of complications and outcomes after TEVAR^ä

Outcomes	No SCI (n=550)	SCI (n=57)	p-value
Length of stay (days±SD)	8.4±11.5	15.5±12.3	<.0001
Death (in-hospital)	35 (6.4)	5 (8.8)	.49

Category, No. (%)

Other^*	60 (10.9)	5 (8.8)	.62
Pulmonary	36 (6.6)	11 (19.3)	.002
Renal	27 (4.9)	6 (10.5)	.11
Ischemic	24 (4.4)	2 (3.5)	1
Bleeding	22 (4.0)	4 (7.0)	.29
Cardiac	19 (3.5)	3 (5.3)	.45
Gastrointestinal	14 (2.6)	2 (3.5)	.66
Wound	7 (1.3)	2 (3.5)	.20

Total number of complications (mean±SD) [95% CI]	.4±.81 [.3–.5]	.65±1 [.4–.9]	.04

^ä

Chi-square or Fischer’s exact test when indicated; TEVAR, thoracic endovascular aortic repair;

Other, includes mycotic, endoleak and device failure complications of the endograft